Specialty Chemical Giant Ashland Explores Sale Under Shareholder Pressure

Specialty chemical supplier Ashland is evaluating a potential sale of the entire company after receiving acquisition interest from multiple suitors, according to Bloomberg. The century-old chemical maker has retained Citigroup and Lazard as financial advisors to review its options.

Private equity firms including Apollo Global Management, Carlyle Group, and Advent International have expressed interest in acquiring the business. Standard Industries, Ashland’s largest shareholder, is also among the prospective buyers. Shares of Ashland surged approximately 6% following news of the potential deal.

Activist Investor Pressure and Board Settlement

Founded in 1924, Ashland originally operated across oil refining and lubricants before divesting legacy assets to specialize in high-value chemical materials. Today, the company is a critical upstream ingredient and technology partner for the global cosmetics industry, supplying active components and functional additives used by major international cosmetics conglomerates and leading independent skin care brands worldwide.

The sale process follows months of escalating pressure from activist shareholders. After Ashland delivered disappointing financial results in April, activist fund Ancora Holdings built a stake and publicly demanded a sale in June, asserting that the company was undervalued and that a transaction could yield a 30% premium for shareholders.

Hedge fund Cruiser Capital Advisors soon joined Ancora in threatening a proxy contest if the board failed to act before the September director nomination deadline. Ashland reached a settlement with Ancora in late July, agreeing to add two independent directors—former Ferro Corporation Chairman Peter Thomas and former Hercules Inc. CFO Allen Spizzo—and establishing a capital allocation advisory committee. Ancora publicly welcomed the settlement, and Ashland subsequently declared a quarterly cash dividend.

Portfolio Performance and Prospective Buyers

Over the past decade, Ashland has reshaped its business portfolio through significant divestitures. The company spun off its Valvoline lubricant unit in 2017, sold its performance adhesives division to Arkema in 2022, and later exited its nutraceuticals and fragrance fixatives businesses to focus strictly on specialty formulations.

Today, Ashland operates across four core divisions: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences serves pharmaceutical and agricultural clients, while Personal Care supplies raw materials for skin care and hair care formulations. Specialty Additives serves construction and automotive markets, and Intermediates produces 1,4-butanediol (BDO) and related specialty chemicals.

Life Sciences remains the company's primary growth engine. In the third quarter of fiscal year 2026 (ended June 30, 2026), the division reported $180 million in revenue, up 11% year-over-year, with adjusted EBITDA rising 11% to $60 million and maintaining an EBITDA margin of 33%.

Personal Care also delivered solid momentum, posting Q3 revenue of $155 million—a 5% year-over-year increase—and a 29% margin. Within the division, biofunctional active ingredients jumped nearly 30%, while skin care ingredients registered high single-digit growth. As beauty brands expand into specialized product categories like complexion and skin coverage formulations, demand for high-performance active ingredients remains a key driver for upstream suppliers.

Specialty Additives generated $136 million in Q3 revenue, acting as a slight drag on short-term profitability. The Intermediates unit recorded $37 million in revenue, where strong demand from electric vehicle battery and energy storage customers was partially offset by reduced tax credits. Total company revenue declined from $2.113 billion to $1.824 billion in fiscal year 2025, largely reflecting intentional asset divestitures rather than organic operational declines.

Institutional analysts estimate that a transaction valued at 13.5x to 15x EV/EBITDA would translate to an acquisition price of $90 to $100 per share. Potential buyers fall into two main categories: private equity firms seeking steady cash flows and high-margin assets with operational upside, and strategic industrial acquirers like Standard Industries. Standard Industries, which holds nearly 10% of Ashland's shares, previously privatized specialty chemical producer W.R. Grace in a $7 billion deal in 2021.

While deal discussions remain ongoing and a transaction is not guaranteed, a sale of Ashland would mark a major consolidation in the global personal care ingredient and pharmaceutical excipient markets.